Immunocompromised Mice

The immune deficit can arise from genetic mutations, targeted depletion of immune cells, or immunosuppressive treatment. These routes create different experimental conditions because they alter immune function through distinct mechanisms. Selecting among them allows investigators to align the model with the biological question, such as examining transplantation, infection, cancer, or therapeutic response.

Reduced immune rejection allows transplanted cells, tissues, or tumors to persist in the mouse rather than being eliminated immediately by a fully functioning immune system. This supports controlled examination of human xenografts and patient-derived tumors in vivo. The resulting model can reveal disease progression and treatment effects within an organism-level setting.

Immune status is an experimental variable rather than merely a background feature. Weakening or removing immune functions can change how transplanted material is maintained and how disease develops in the model. Consequently, treatment responses observed in immunocompromised mice must be interpreted in relation to the specific immune deficit used and the biological process under study.

Cell-based experiments can isolate particular biological interactions, whereas mouse models allow investigators to examine disease progression and treatment effects in vivo. Immunocompromised mice help bridge these levels of investigation by supporting human cell, tissue, or tumor studies within a living organism. This added context can clarify outcomes that are difficult to assess in isolated cells.

Researchers establish these models through three approaches described in the source material: using mice with genetic mutations, selectively depleting immune cells, or applying immunosuppressive treatments. The chosen approach determines how immune function is reduced before the disease, transplant, or therapy study. That design step is central to matching the model with the intended experimental question.

Human xenografts and patient-derived tumors are useful when investigators need to study human cancer material in a living system. Immunocompromised mice reduce rejection of these transplanted materials, enabling observation of disease progression and treatment effects. These models therefore support cancer research and therapeutic development while connecting findings from human-derived samples with organism-level responses.